The central government has approved two more Covid vaccines to use in India. Corbevax and Covovax are the two vaccines cleared by the government in its recent move. Apart from the vaccines, the anti-viral drug Molnupiravir can also be used during emergencies, informed Union Health Minister Mansukh Mandaviya.
Covovax was developed by the Serum Institute and Corbevax belongs to the biological EU. Malnupiraveer is approved for use in adults in emergencies. Also, Corbevax is India’s first homegrown “RBD protein sub-unit vaccine”, Health Minister Mansukh Mandaviya tweeted on December 28, The Mint reported.
A Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorization (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions. The decision of approving the vaccines was then taken and it was announced by the Union Health Minister.
The nanoparticle vaccine, Covovax, will be manufactured by the Pune-based SII. The other two vaccines developed in India are Bharat Biotech’s Covaxin and the Serum Institute of India’s (SII) Covishield. With the latest approvals, a total of eight COVID-19 vaccines have got emergency use authorization from India’s drug regulators – Covishield, Covaxin, ZyCoV-D, Sputnik V, Moderna, Johnson and Johnson, Corbevax, and Covovax.
Meanwhile, Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situation for the treatment of adult patients with Covid-19 and who have a high risk of progression of the disease.